Tamer M. Mohamed, Ph.D.

Assistant Professor of Medicine

Department of Medicine, Division of Cardiovascular Medicine

E-mail 502-852-8428

Education and Training

Ph.D.: University of Manchester, Cardiovascular and Molecular Medicine
Postdoctoral Fellowship: University of Manchester; Gladstone Institutes, Cardiology

Research Interests

My main research interest is to identify novel therapies for heart failure focusing on endogenous heart repair and regeneration mechanisms. As a pharmacist by training and the unique combination of academic and industry experience, my major aim is to perform translational research which directly benefits heart failure patients.

During my research endeavors, I have studied novel mechanisms and therapies for cardiac hypertrophy and heart failure in animal models. During my doctoral and first postdoctoral training, I identified the role of the plasma membrane calcium ATPase isoform 4 (PMCA4) in cardiac physiology and pathophysiology.

As a pharmacist, I have a special interest in translating my findings into human drug therapies for heart disease. Thus, I started screening drugs to identify the first specific inhibitor for PMCA4, which could then be used as a novel treatment for cardiac hypertrophy and heart failure. Recently, in collaboration with the Fraunhofer Institute in Germany, the Medical Research Council in the UK, and the drug company Astra Zeneca, we created a program to identify new drugs that treat heart failure by targeting PMCA4.

To expand my expertise in cardiac regeneration, I joined Prof. Deepak Srivastava's laboratory at the Gladstone Institutes in August 2013. In the Srivastava lab I acquired training on cutting-edge technology for direct cardiac reprogramming, and profiling single-cell genomes and epigenomes during the reprogramming process. The skills that I have learned while working with Prof. Srivastava will be invaluable to running my independent laboratory.

I worked on two parallel approaches to induce endogenous heart repair: direct cardiac reprogramming and inducing cardiomyocyte proliferation. Both approaches were highly successful. The direct reprogramming project was highly recognized by our scientific community, as it was awarded a Scientist Development Grant award from the American Heart Association, manuscript was published in Circulationand this work was chosen as finalist at the Louis N. and Arnold M. Katz Basic Science Research Prize for Young Investigators from the AHA in 2016.

In addition, the cardiomyocyte proliferation project was accepted for publication in Cell and awarded the March 22, 2018 issue cover for the journal. In October 2016 Dr. Srivastava has founded a new start up (Tenaya Therapeutics) with $50 million investment from the column group to develop new therapies for heart failure based on my findings. Therefore, I was the first scientist recruited to the company to lead the efforts of direct cardiac reprogramming where I enjoyed the unique industry experience in building a start up from scratch.

In Tenaya I was able to establish novel system for long term culture of human heart slices and efficiently demonstrating direct cardiac reprogramming in such pre-clinical models. In addition, I was able to reduce the number of essential reprogramming factors in human cardiac fibroblasts to 3 essential factors where they are now under pre-clinical testing for in vivo efficiency in large animals (pigs). Due to the quick success in Tenaya, the research and development section ended very soon and now the major focus on scaling up viral manufacturing and filing IND which is away from my interest.

Therefore, I have decided to go back to academia to initiate new discoveries to treat heart failure mainly focusing on understanding the reprogramming process and cell cycle regulation of cardiomyocyte proliferation.

Featured Publications

  • Stafford N, Zi M, Baudoin F, Mohamed TMA, Prehar S, De Giorgio D, Cartwright EJ, Latini R, Neyses L, Oceandy D. PMCA4 inhibition does not affect cardiac remodelling following myocardial infarction, but may reduce susceptibility to arrhythmia. Sci Rep. 2021 Jan 15;11(1):1518. doi: 10.1038/s41598-021-81170-2. PMID: 33452399; PMCID: PMC7810749.
  • Meki MH, Miller JM, Mohamed TMA. Heart Slices to Model Cardiac Physiology. Front Pharmacol. 2021 Feb 4;12:617922. doi: 10.3389/fphar.2021.617922. PMID: 33613292; PMCID: PMC7890402.
  • Mohamed TMA, Conklin DJ. Emerging technology and platforms for cardiotoxicity testing. Toxicol Appl Pharmacol. 2020 Dec 1;408:115262. doi: 10.1016/j.taap.2020.115262. Epub 2020 Oct 2. PMID: 33017593; PMCID: PMC7747951.
  • Miller JM, Meki MH, Ou Q, George SA, Gams A, Abouleisa RRE, Tang XL, Ahern BM, Giridharan GA, El-Baz A, Hill BG, Satin J, Conklin DJ, Moslehi J, Bolli R, Ribeiro AJS, Efimov IR, Mohamed TMA. Heart slice culture system reliably demonstrates clinical drug-related cardiotoxicity. Toxicol Appl Pharmacol. 2020 Nov 1;406:115213. doi: 10.1016/j.taap.2020.115213. Epub 2020 Aug 30. PMID: 32877659; PMCID: PMC7554180.
  • Ou Q, Abouleisa RRE, Tang XL, Juhardeen HR, Meki MH, Miller JM, Giridharan G, El-Baz A, Bolli R, Mohamed TMA. Slicing and Culturing Pig Hearts under Physiological Conditions. J Vis Exp. 2020 Mar 20;(157):10.3791/60913. doi: 10.3791/60913. PMID: 32250357; PMCID: PMC7388059.
  • Abdeltawab H, Khalifa F, Taher F, Alghamdi NS, Ghazal M, Beache G, Mohamed T, Keynton R, El-Baz A. A deep learning-based approach for automatic segmentation and quantification of the left ventricle from cardiac cine MR images. Comput Med Imaging Graph. 2020 Apr;81:101717. doi: 10.1016/j.compmedimag.2020.101717. Epub 2020 Mar 12. PMID: 32222684; PMCID: PMC7232687.
  • Ou Q, Jacobson Z, Abouleisa RRE, Tang XL, Hindi SM, Kumar A, Ivey KN, Giridharan G, El-Baz A, Brittian K, Rood B, Lin YH, Watson SA, Perbellini F, McKinsey TA, Hill BG, Jones SP, Terracciano CM, Bolli R, Mohamed TMA. Physiological Biomimetic Culture System for Pig and Human Heart Slices. Circ Res. 2019 Aug 30;125(6):628-642. doi: 10.1161/CIRCRESAHA.119.314996. Epub 2019 Jul 16. PMID: 31310161; PMCID: PMC6715512.
  • Stone NR, Gifford CA, Thomas R, Pratt KJB, Samse-Knapp K, Mohamed TMA, Radzinsky EM, Schricker A, Ye L, Yu P, van Bemmel JG, Ivey KN, Pollard KS, Srivastava D. Context-Specific Transcription Factor Functions Regulate Epigenomic and Transcriptional Dynamics during Cardiac Reprogramming. Cell Stem Cell. 2019 Jul 3;25(1):87-102.e9. doi: 10.1016/j.stem.2019.06.012. PMID: 31271750; PMCID: PMC6632093.
  • Mohamed TMA, Ang YS, Radzinsky E, Zhou P, Huang Y, Elfenbein A, Foley A, Magnitsky S, Srivastava D. Regulation of Cell Cycle to Stimulate Adult Cardiomyocyte Proliferation and Cardiac Regeneration. Cell. 2018 Mar 22;173(1):104-116.e12. doi: 10.1016/j.cell.2018.02.014. Epub 2018 Mar 1. PMID: 29502971; PMCID: PMC5973786.
  • Hegab Z, Mohamed TMA, Stafford N, Mamas M, Cartwright EJ, Oceandy D. Advanced glycation end products reduce the calcium transient in cardiomyocytes by increasing production of reactive oxygen species and nitric oxide. FEBS Open Bio. 2017 Sep 26;7(11):1672-1685. doi: 10.1002/2211-5463.12284. PMID: 29123976; PMCID: PMC5666397.